[go: up one dir, main page]

DK2528602T4 - Formuleringer af bendamustin - Google Patents

Formuleringer af bendamustin Download PDF

Info

Publication number
DK2528602T4
DK2528602T4 DK11737745.7T DK11737745T DK2528602T4 DK 2528602 T4 DK2528602 T4 DK 2528602T4 DK 11737745 T DK11737745 T DK 11737745T DK 2528602 T4 DK2528602 T4 DK 2528602T4
Authority
DK
Denmark
Prior art keywords
bendamustin
formulations
Prior art date
Application number
DK11737745.7T
Other languages
English (en)
Other versions
DK2528602T3 (da
Inventor
Nagesh R Palepu
Philip Christopher Buxton
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44309429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2528602(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of DK2528602T3 publication Critical patent/DK2528602T3/da
Application granted granted Critical
Publication of DK2528602T4 publication Critical patent/DK2528602T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK11737745.7T 2010-01-28 2011-01-28 Formuleringer af bendamustin DK2528602T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29910010P 2010-01-28 2010-01-28
PCT/US2011/022958 WO2011094565A1 (en) 2010-01-28 2011-01-28 Formulations of bendamustine

Publications (2)

Publication Number Publication Date
DK2528602T3 DK2528602T3 (da) 2017-01-23
DK2528602T4 true DK2528602T4 (da) 2020-04-27

Family

ID=44309429

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16020363.4T DK3158991T3 (da) 2010-01-28 2011-01-28 Formuleringer af bendamustin
DK11737745.7T DK2528602T4 (da) 2010-01-28 2011-01-28 Formuleringer af bendamustin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK16020363.4T DK3158991T3 (da) 2010-01-28 2011-01-28 Formuleringer af bendamustin

Country Status (16)

Country Link
US (14) US8609707B2 (da)
EP (3) EP3158991B1 (da)
JP (2) JP5795600B2 (da)
CA (1) CA2787568C (da)
CY (2) CY1118769T1 (da)
DK (2) DK3158991T3 (da)
ES (2) ES2875374T3 (da)
HR (2) HRP20161771T4 (da)
HU (2) HUE031208T2 (da)
LT (2) LT3158991T (da)
PL (2) PL2528602T5 (da)
PT (2) PT3158991T (da)
RS (2) RS62327B1 (da)
SI (2) SI2528602T2 (da)
SM (3) SMT201700043T1 (da)
WO (1) WO2011094565A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2528602T5 (pl) 2010-01-28 2020-09-07 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
US20130210878A1 (en) * 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
WO2013123227A1 (en) * 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
DK2827862T3 (da) * 2012-03-20 2024-02-12 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
WO2013142359A1 (en) * 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
MX376522B (es) 2013-08-27 2025-03-07 Vasilios Voudouris Composiciones farmacéuticas de bendamustina.
AU2014322111A1 (en) * 2013-09-20 2016-04-07 Santen Pharmaceutical Co., Ltd. Polyethylene glycol-containing composition
US20160235717A1 (en) * 2013-10-11 2016-08-18 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
CN115350155A (zh) * 2014-03-13 2022-11-18 V·沃道里斯 苯达莫司汀固体分散体和连续输液
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
EP3370710A1 (en) * 2015-11-04 2018-09-12 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
US10905677B2 (en) * 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11752135B2 (en) 2018-03-29 2023-09-12 Project Pharmaceutics Gmbh Liquid pharmaceutical formulation
WO2020035806A1 (en) 2018-08-17 2020-02-20 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP2020090481A (ja) * 2018-11-27 2020-06-11 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
WO2020170104A1 (en) * 2019-02-18 2020-08-27 Shilpa Medicare Limited Liquid bendamustine parenteral compositions
JPWO2021161876A1 (da) * 2020-02-10 2021-08-19
EP4419147A1 (en) 2021-10-22 2024-08-28 Project Pharmaceutics GmbH Liquid pharmaceutical formulation
GB202118175D0 (en) 2021-12-15 2022-01-26 Arecor Ltd Novel composition
US11707450B1 (en) 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (da) * 1903-10-08 1905-03-16
DE152989C (da)
DE80967C (da)
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD152989A1 (de) 1980-09-11 1981-12-16 Klaus Kunze Anordnung zur korrektur von soll-und istwerten
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
ATE187071T1 (de) 1993-10-27 1999-12-15 Upjohn Co Stabilisiertes prostaglandin e1
CA2181241C (en) * 1994-01-24 2000-04-25 Dadi Jamshed Dhabhar Process for solubilizing difficultly soluble pharmaceutical actives
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
JP2002511878A (ja) 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
ATE526022T1 (de) * 1998-04-20 2011-10-15 Eisai R&D Man Co Ltd Stabilisierte zusammenstellungen die benzimidazole enthalten
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
JP2005538030A (ja) 2000-06-21 2005-12-15 デュポン ファーマシューティカルズ カンパニー 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
CA2413957A1 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2001097861A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
EP1311301A2 (en) 2000-07-06 2003-05-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
US20060001597A1 (en) 2004-06-30 2006-01-05 Sokbom Han Image processing apparatus, systems and associated methods
JP2008519047A (ja) 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
US20090156670A1 (en) 2004-11-22 2009-06-18 Venus Remedies Limited Nonaqueous liquid parenteral aceclofenac formulation
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
AU2006235183B2 (en) 2005-04-08 2011-02-10 Amylin Pharmaceuticals, Llc Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1850048A (zh) 2006-06-09 2006-10-25 山东蓝金生物工程有限公司 一种含血管抑制剂的抗癌缓释注射剂
AU2007285215A1 (en) 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Stable lyophilized preparation
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
KR20110110293A (ko) 2009-01-15 2011-10-06 세파론, 인코포레이티드 벤다무스틴 유리 염기의 신규 형태
RU2591804C2 (ru) 2009-02-25 2016-07-20 Супратек Фарма, Инк. Композиции бендамустина и циклополисахарида
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
EP2424506A1 (en) * 2009-04-28 2012-03-07 Cephalon, Inc. Oral formulations of bendamustine
CN101584668A (zh) 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US7772274B1 (en) * 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
PL2528602T5 (pl) * 2010-01-28 2020-09-07 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CA2804855A1 (en) 2010-07-28 2012-02-02 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
WO2012170384A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
AU2012347972B2 (en) 2011-12-05 2018-05-10 X-Body, Inc. PDGF receptor beta binding polypeptides
CA2857177C (en) 2011-12-05 2020-06-23 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
US20130210878A1 (en) 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
WO2013123227A1 (en) 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2013142359A1 (en) 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
DK2827862T3 (da) 2012-03-20 2024-02-12 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
JP6331468B2 (ja) 2014-02-27 2018-05-30 住友ベークライト株式会社 金属ラミネート用フィルム、ラミネート金属板および金属容器
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Also Published As

Publication number Publication date
US10010533B2 (en) 2018-07-03
DK2528602T3 (da) 2017-01-23
SMT202100348T1 (it) 2021-07-12
CA2787568C (en) 2019-04-02
US20110184036A1 (en) 2011-07-28
HRP20161771T4 (hr) 2020-08-07
RS55491B1 (sr) 2017-04-28
US20190350904A1 (en) 2019-11-21
EP2528602A1 (en) 2012-12-05
DK3158991T3 (da) 2021-06-14
WO2011094565A1 (en) 2011-08-04
SI3158991T1 (sl) 2021-10-29
ES2609106T5 (es) 2020-11-10
EP2528602B2 (en) 2020-02-12
SMT201700043T1 (it) 2017-03-08
EP3158991B1 (en) 2021-03-17
HUE031208T2 (hu) 2017-07-28
RS55491B2 (sr) 2020-11-30
LT3158991T (lt) 2021-07-12
US20160143887A1 (en) 2016-05-26
SI2528602T2 (sl) 2020-10-30
US20240293372A1 (en) 2024-09-05
EP2528602B1 (en) 2016-10-05
PT2528602T (pt) 2017-01-12
LT2528602T (lt) 2017-02-27
JP5795600B2 (ja) 2015-10-14
HRP20161771T1 (hr) 2017-02-24
US11872214B2 (en) 2024-01-16
US9572797B2 (en) 2017-02-21
CY1124262T1 (el) 2022-07-22
SMT201700043B (it) 2017-03-08
ES2875374T3 (es) 2021-11-10
US8609707B2 (en) 2013-12-17
US9265831B2 (en) 2016-02-23
US20180296536A1 (en) 2018-10-18
JP6133943B2 (ja) 2017-05-24
US11103483B2 (en) 2021-08-31
US20230115693A1 (en) 2023-04-13
PL3158991T3 (pl) 2021-09-27
EP2528602A4 (en) 2014-01-22
US20140024691A1 (en) 2014-01-23
ES2609106T3 (es) 2017-04-18
CY1118769T1 (el) 2017-07-12
JP2013518130A (ja) 2013-05-20
US9572796B2 (en) 2017-02-21
HUE054836T2 (hu) 2021-10-28
EP3895694A1 (en) 2021-10-20
US20240293373A1 (en) 2024-09-05
US20180000789A1 (en) 2018-01-04
US20240075013A1 (en) 2024-03-07
EP3158991A1 (en) 2017-04-26
SI2528602T1 (sl) 2017-03-31
PT3158991T (pt) 2021-06-23
RS62327B1 (sr) 2021-10-29
PL2528602T3 (pl) 2017-03-31
HRP20210915T1 (hr) 2021-10-01
PL2528602T5 (pl) 2020-09-07
JP2016020365A (ja) 2016-02-04
US20230115164A1 (en) 2023-04-13
US11844783B2 (en) 2023-12-19
US12138248B2 (en) 2024-11-12
CA2787568A1 (en) 2011-08-04
US20210393594A1 (en) 2021-12-23
US20160143888A1 (en) 2016-05-26
US20180296535A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
DK2528602T4 (da) Formuleringer af bendamustin
DK2498756T3 (da) Tabletformuleringer af neratinibmaleat
DK2567524T3 (da) Reduktion af protokolspild
DK3725778T3 (da) Formuleringer af enzalutamid
DK3156056T3 (da) Farmaceutiske sammensætninger der består af sorbitanestere
DK3235812T3 (da) Deutererede derivater af ivacaftor
RS56220B1 (sr) Farmaceutski sastav karbetocina
DK2603232T3 (da) Stabile formuleringer af linaclotid
DK2640893T4 (da) Sammensætninger
IL223725B (en) Formulations of rifaximin and uses thereof
DK2633006T3 (da) Fremstilling af fornybart bio-destillat
DK2827862T3 (da) Formuleringer af bendamustin
DK3831406T3 (da) Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
DK2555704T3 (da) Visning af hæmostatiske parametre
DK2822568T3 (da) Anvendelser af caseinsammensætninger
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
EP2552212A4 (en) IMPROVED FORMULATION
DK2800572T3 (da) Sammensætning af ellagitannin-rige ekstrakter
EP2531023A4 (en) IMPROVED FORMULATION
DK2648696T3 (da) Ny indgivelsesform af racecadotril
PT2402012E (pt) Formulações líquidas de fumarato de rupatadina
SMT201600380B (it) Formulazioni di darunavir
DK2925338T3 (da) Frysetørret formulering af tat-nr2b9c
DK2571843T3 (da) Forbedret fremstilling af chalcon-derivater
DK2858989T3 (da) Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil